ClinicalTrials.gg
RecruitingNCT05256251We-LongevityUpdated Sep 29, 2026

Westlake Longevity Cohort

An observational study in Aging, sponsored by Westlake University. Recruiting at 1 site in China. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Westlake University · Observational

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.
Updated Sep 29, 2026Primary completion movedEnrollment updated+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,800
Ages
50 Years and older
Sex
All
01

Study summary

The Westlake Longevity Cohort (We-Longevity) is a prospective cohort study among centenarians, nonagenarians and senior citizens living in Zhejiang Province, China. The primary aim of this cohort is to characterize the multi-omics molecular characteristics of healthy longevity and their dynamic trajectories. The second aim is to culture the gut microbiota of these elderly people through culturomics. The third aim of We-Longevity is to investigate the association of dietary and lifestyle with the multi-omics molecular characteristics of healthy longevity, and to facilitate the development of personalized nutritional/lifestyle recommendation for the public.

Read the detailed description

Aging is a major risk factor for most fatal diseases, such as Alzheimer's disease, type 2 diabetes, cardiovascular disease, and cancer. Global population aging is becoming increasingly serious, and this trend is mainly driving the annual increase in the prevalence of aging-related diseases. Healthy longevity is influenced by a variety of factors, such as diet structure, lifestyle, ecological environment, gut microbiome, and genetics. At present, research on healthy longevity is mainly focused on Drosophila, nematodes, and mouse models, but few studies have targeted longevity populations. Centenarians and nonagenarians are the best populations to study healthy longevity. However, the multi-omics molecular characteristics and regulatory mechanisms of healthy longevity in humans are still unclear. Therefore, the We-Longevity design includes centenarians, nonagenarians, and senior citizens. We will determine the fecal/serum metabolome, culturable gut microbiome characteristics, gut microbiome, serum proteome, and genome, together with diet, lifestyle, and disease information.

02

Conditions studied

  • Aging

Keywords

  • Gut microbiome
  • Aging
03

In context

Lead sponsor

Westlake University is the lead sponsor of 28 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Sep 29, 2026. See what changed

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All the participants should be Chinese residents, regardless of the ethics.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants live in Zhejiang Province, China.
  • Participants intend to remain in Zhejiang Province for ≥3 years.

Exclusion criteria

Exclusion Criteria:

  • Participants with infectious diseases.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,800 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Physical frailty

    Physical frailty will be evaluated by using Fried's criteria.

    Time frame: 1 year

  2. Gut microbiome

    Fecal microbiome will be analyzed by 16S/ITS rRNA gene sequencing and metagenome sequencing. Furthermore, fecal microbiota will be cultured, picked and identified.

    Time frame: 3 months, 1 year

Secondary outcomes

  1. Cognitive function

    Cognitive function will be evaluated by using Mini-Mental State Examination (MMSE).

    Time frame: 1 year

  2. Metabolomics profiling

    Relative abundance of blood and fecal metabolites will be analyzed by LC-MS/MS.

    Time frame: 1 year

  3. All-cause survival status

    Survival status will be ascertained through data collected from nursing home follow-up surveys.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Lishui Yikang Hospital, Renji Nursing Home, Lihong Nursing Home, Nancheng Nursing Home
    Lishui, Zhejiang 323000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2021 (actual). Primary completion is estimated for Nov 2028, 83 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2025 → Nov 2028, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2021
First posted
Feb 25, 2022
StartActual
Nov 15, 2021
Primary completionEst.
Nov 14, 2028was Nov 2025
CompletionEst.
Nov 14, 2031
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Lishui Yikang Hospital, Renji Nursing Home, Lihong Nursing Home, Nancheng Nursing Home · Lishui, China
Show 1 removed
  • Lishui Yikang Hospital · Lishui, China
Sep 29, 2026
Primary completion
Nov 14, 2025→Nov 14, 2028
Sep 29, 2026
Enrollment
1500→2800
Sep 29, 2026
Eligibility
Minimum age none→50 Years; 2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedParticipants live in LishuiZhejiang Province, China.
  • EditedParticipants intend to remain in LishuiZhejiang Province for ≥3 years.
Sep 29, 2026
Primary outcomes
2 time frame changed
What changed in the outcomes
  • Time framePhysical frailty36 months → 1 year
  • Time frameGut microbiome36 months → 3 months, 1 year
Sep 29, 2026
Secondary outcomes
1 edited, 2 time frame changed, 1 description edited
What changed in the outcomes
  • ChangedBefore Blood biochemical parametersNow All-cause survival statusTime frame: 36 months → 1 year
  • Time frameCognitive function36 months → 1 year
  • Time frameMetabolomics profiling36 months → 1 year
  • DescriptionMetabolomics profiling: how it is measured was reworded
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    1 site added, 1 site removed
    Show site
    • Lishui Yikang Hospital, Renji Nursing Home, Lihong Nursing Home, Nancheng Nursing Home · Lishui, China
    Show 1 removed
    • Lishui Yikang Hospital · Lishui, China
    Primary completion Nov 14, 2025→Nov 14, 2028
    Enrollment 1500→2800
    Eligibility Minimum age none→50 Years; 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedParticipants live in LishuiZhejiang Province, China.
    • EditedParticipants intend to remain in LishuiZhejiang Province for ≥3 years.
    Primary outcomes 2 time frame changed
    What changed in the outcomes
    • Time framePhysical frailty36 months → 1 year
    • Time frameGut microbiome36 months → 3 months, 1 year
    Secondary outcomes 1 edited, 2 time frame changed, 1 description edited
    What changed in the outcomes
    • ChangedBefore Blood biochemical parametersNow All-cause survival statusTime frame: 36 months → 1 year
    • Time frameCognitive function36 months → 1 year
    • Time frameMetabolomics profiling36 months → 1 year
    • DescriptionMetabolomics profiling: how it is measured was reworded
    + 4 other changes: verification date, oversight details, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05256251
Lead sponsor
Westlake University
Responsible party
Sponsor
First posted
Feb 25, 2022
Start date
Nov 15, 2021
Primary completion
Nov 14, 2028 (estimated)
Completion
Nov 14, 2031 (estimated)
Last update
Sep 29, 2026

Study contacts

Ju-Sheng Zheng, PhD
Contact
zhengjusheng@westlake.edu.cn
86-0571-86915303
Junhui Zhang, PhD
Contact
zhangjunhui@westlake.edu.cn
86-0571-86915303
Ju-Sheng Zheng, PhD
principal investigator · Westlake University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion